Statistics from Altmetric.com
Despite the treatments available for type 2 diabetes, about two-thirds of these patients die from associated heart disease or stroke.1 Approval of the first glucagon-like peptide-1 agonist (GLP-1), exenatide, by the FDA in 2005 generated an expectation that the clinical outcomes in type 2 diabetes would be improved. However, we still do not have definitive evidence that exenatide does this, although a clinical trial to determine this, the Exenatide Study of Cardiovascular Even Lowering (EXSCEL) trial, is under way.2 Subsequently, other GLP-1 receptor agonists, including liraglutide, have also been approved and used for 10 years without clinical outcome data.3 Recently, the results of Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.